{
    "clinical_study": {
        "@rank": "168121", 
        "acronym": "ProMETheX", 
        "arm_group": [
            {
                "arm_group_label": "capecitabine", 
                "arm_group_type": "Other", 
                "description": "patients treated by capecitabine alone (n=100)"
            }, 
            {
                "arm_group_label": "capecitabine + lapatinib", 
                "arm_group_type": "Other", 
                "description": "patients treated by capecitabine and lapatinib (n=100)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of the implementation of an\n      educational program on adherence to capecitabine alone or in combination to lapatinib."
        }, 
        "brief_title": "Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Breast Cancer", 
            "Colorectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "200 subjects who meet the inclusion/exclusion criteria treated by capecitabine +/-\n      lapatinib, will be enrolled into the study. Adherence to treatment of all subjects will be\n      assessed during a first adherence evaluation period of 3 cycles in order to identify\n      patients who need educational intervention(non adherent patients). Only nonadherent patients\n      (adherence rate < 80%) will receive an education intervention. During the educational\n      program, the efficacy of the implementation of an educational program on adherence to\n      capecitabine alone or in combination to lapatinib will be evaluated for the 6 subsequent\n      cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age> 18 years\n\n          -  histologically confirmed breast cancer or colorectal cancer\n\n          -  Patient starting oral treatment : capecitabine alone or in combination with lapatinib\n             (can be included before the first cycle or during the first 2 cycles).\n\n          -  Volunteer to participate in the study.\n\n          -  ambulatory treated patient\n\n          -  Able to read, write and understand French.\n\n          -  Subject who accept to use MEMS monitors to automatically compile their drug dosing\n             histories\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  more than 3 metastatic chemotherapies\n\n          -  any severe concomitant condition which makes it undesirable for the patient to\n             participate in the study or which would jeopardize adherence with trial protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847599", 
            "org_study_id": "2010-A01300-39"
        }, 
        "intervention": {
            "arm_group_label": [
                "capecitabine", 
                "capecitabine + lapatinib"
            ], 
            "intervention_name": "Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil", 
                "Lapatinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "educational intervention", 
            "adherence", 
            "capecitabine", 
            "lapatinib"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "email": "Isabelle.VANPRAAGH@cjp.fr", 
                "last_name": "Isabelle VAN-PRAAGH, MD", 
                "phone": "33473278089"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont Ferrand", 
                    "country": "France", 
                    "zip": "63011"
                }, 
                "name": "Centre Jean Perrin"
            }, 
            "investigator": {
                "last_name": "Isabelle VAN-PRAAGH, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Implementation of a Therapeutic Educational Program Applicated to Adherence of Patients Treated by Capecitabine Alone or in Combination With Lapatinib", 
        "overall_contact": {
            "email": "emilie.thivat@cjp.fr", 
            "last_name": "Emilie THIVAT, PhD", 
            "phone": "33473278089"
        }, 
        "overall_official": {
            "affiliation": "Centre Jean Perrin", 
            "last_name": "Isabelle VAN PRAAGH, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the efficacy of the implementation of an educational program will be evaluated by adherence assessment using electronic monitoring system", 
            "measure": "evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib", 
            "safety_issue": "No", 
            "time_frame": "every visit during 3 cycles i.e. 9 weeks (adherent patients) and for 6 additional cycles i.e. 18 weeks during educational intervention (nonadhererent patients)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "patient satisfaction to the educational program as determined by questionnaire", 
                "safety_issue": "No", 
                "time_frame": "at the end of the educational program i.e. approximately during the week 27"
            }, 
            {
                "measure": "safety and tolerability as determined by adverse events frequency", 
                "safety_issue": "Yes", 
                "time_frame": "for 3 cycles e.i. 9 weeks (adherent patients) or 9 cycles e.i. 27 weeks (nonadherent patients)"
            }
        ], 
        "source": "Centre Jean Perrin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Jean Perrin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}